Enhanced Investments - Financial Portal

Illumina to showcase the transformational impact of comprehensive genomic profiling in unlocking precision medicine for cancer patients, at ASCO

Published: 2022-06-02 17:10:00 ET

SAN DIEGO, June 2, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the acceptance of seven key oncology research abstracts authored in collaboration with Illumina at the American Society of Clinical Oncology (ASCO) annual meeting taking place June 3 – June 7 in Chicago. In addition, Illumina will host a related event, "Unlocking Precision Medicine: The Transformational Impact of Comprehensive Genomic Profiling," featuring Chief Medical Officer, Phil Febbo, MD; Kevin Keegan, Vice President and General Manager, Oncology; and a panel of leading oncologists from select community and academic programs.

"At Illumina, we are seeing increased adoption of comprehensive genomic profiling in both in-house pathology labs and centralized labs to inform and enhance patient care," said Keegan. "Through our involvement in this year's ASCO, we look forward to learning more about and exploring the comprehensive genomic profiling experiences of leading oncology researchers to help inform this important work moving forward."

Illumina's mission in oncology is to save lives by enabling personalized cancer care through genomics. This includes increasing enablement for pathology labs to perform comprehensive genomic profiling for cancer tumors.

Comprehensive genomic profiling is a next-generation sequencing (NGS) approach that uses a single test to assess hundreds of genes including relevant cancer biomarkers, as established in medical guidelines and clinical trials, for solid tumor therapy guidance. CGP is being increasingly adopted by pathologists and oncologists to enhance their abilities to identify actionable biomarkers, which can lead to better matches between patients and precision therapies and clinical trials. Studies show that patients who receive a genomic match to biomarker-driven targeted therapies or immunotherapies experience improved clinical outcomes.

"For a physician, the priority is finding the best course of therapy for the patient as quickly as possible," said Dr. Febbo. "With a rapidly growing catalogue of targeted drugs and immunotherapies for many cancer types we are increasingly able to prescribe more and more personalized treatments. In addition, pan cancer markers identify an important group of patients that benefit from targeted therapy regardless of their tumor's tissue of origin."

Abstracts accepted at ASCO

Collaborations across the oncology field are vital to increasing clinical utility evidence for comprehensive genomic profiling (CGP). Illumina is proud to present the following results of joint studies at ASCO:

Identification of Clinically Actionable Biomarkers via Routine CGP Across a Large Community Health System, is an abstract summarizing data from a joint study between Illumina and Providence Health System. The results show the improvement in identification of clinically actionable biomarkers via routine CGP versus conventional testing methods (clinical actionability: 45% CGP vs. 19% small panel, p

Enhanced Investments, Inc.
329 South Oyster Bay Road #2085
Plainview, NY 11803
team@eninvs.com

Important disclosures

Performance results were prepared by Enhanced Investments, and have not been compiled, reviewed or audited by an independent accountant. Performance estimates are subject to future adjustment and revision. Investors should be aware that a loss of investment is possible. Account holdings are for illustrative purposes only and are not investment recommendations. Additional information, including (i) the calculation methodology; and (ii) a list showing the contribution of each holding to the portfolio’s performance during the time period will be provided upon request.
All statements made via social media sites sponsored or maintained by Enhanced Investments and its affiliates are for informational purposes only and do not constitute a comprehensive description of Enhanced Investments' investment advisory services.
Certain investments are not suitable for all investors. Before investing, consider your investment objectives and applicable fees. The rate of return on investments can vary widely over time, especially for long term investments. Investment losses are possible, including the potential loss of all amounts invested. Information provided by Enhanced Investments is for informational and general educational purposes only and is not investment or financial advice.

Nothing on this website should be considered an offer, solicitation of an offer, or advice to buy or sell securities.
Past performance is no guarantee of future results. Any historical returns, expected returns [or probability projections] are hypothetical in nature and may not reflect actual future performance.
All the strategies assume investments in equity invstrumenta only and are more relevant for "agressive investment profile". Eastern European flagship strategy assumes using up to 20% leverage of total portfolio. GlobalCommodities and US Growth strategy currently assume no leverage.
Results for the Enhanced Investments strategies as compared to the performance of Illustrative Benchmarks is for informational purposes only. Our investment program does not mirror that of the Illustrative Benchmarks and the volatility may be materially different from the volatility of Illustrative Benchmarks. Reference or comparison to an Illustrative Benchmark does not imply that strategies of Enhanced Investments will be constructed in the same way as the Illustrative Benchmark or achieve returns, volatility, or other results similar to those of the Illustrative Benchmark. The S&P 500 is an unmanaged market capitalization-weighted index of 500 common stocks chosen for market size, liquidity, and industry group representation to represent U.S. equity performance.
Performance results were prepared by Enhanced Investments, and have not been compiled, reviewed or audited by an independent accountant. Performance estimates are subject to future adjustment and revision. Investors should be aware that a loss of investment is possible. Account holdings are for illustrative purposes only and are not investment recommendations. Additional information, including (i) the calculation methodology; and (ii) a list showing the contribution of each holding to the portfolio’s performance during the time period will be provided upon request.
All statements made via social media sites sponsored or maintained by Enhanced Investments and its affiliates are for informational purposes only and do not constitute a comprehensive description of Enhanced Investments' investment advisory services.
Certain investments are not suitable for all investors. Before investing, consider your investment objectives and applicable fees. The rate of return on investments can vary widely over time, especially for long term investments. Investment losses are possible, including the potential loss of all amounts invested. Information provided by Enhanced Investments is for informational and general educational purposes only and is not investment or financial advice.